About
DiaGyn is developing a wide range of solutions targeting unmet needs in the area of womens health, integrating drug development and molecular genomics with personalized therapeutic approaches. The company is focused on addressing BRCA1/2 mutations in ovarian and breast cancer using a treatment strategy based on nanoparticle technology. DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). The innovative product comprises 100 nm mesoporous silica nanoparticles (MSNP) loaded with the antineoplastic docetaxel and capped with the cyclic oligosaccharide cyclodextrin. The cyclodextrin cap linked to the silica particles prevents the uncontrolled release of chemotherapy from the pores before arrival at the intended site. The special design of DiaGyns nanoparticles involves a sensitive linker that selectively senses the high levels of -galactosidase and low pH encountered in the surrounding EOC cells, releasing the drug into the malignant cells while leaving normal tissues largely unaffected. DiaGyn is a subsidiary of Goldman Hirsh Partners.
Q&A
- What is DiaGyn's primary focus?
- DiaGyn is focused on developing targeted chemotherapy for breast and ovarian cancer, specifically addressing BRCA1/2 mutations using nanoparticle technology.
- What is the status of DiaGyn?
- DiaGyn is currently inactive, having ceased operations in December 2022.
- What product has DiaGyn developed?
- DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). This product uses 100 nm mesoporous silica nanoparticles loaded with docetaxel and capped with cyclodextrin.
- How does DiaGyn's nanoparticle technology work?
- The special design of DiaGyn's nanoparticles includes a sensitive linker that selectively senses high levels of β-galactosidase and low pH in the surrounding EOC cells, releasing the drug into malignant cells while largely sparing normal tissues.
- When was DiaGyn founded?
- DiaGyn was founded in September 2015.
- Who is a co-founder of DiaGyn?
- Roy Farfara is a co-founder of DiaGyn.
- What is DiaGyn's current product stage?
- DiaGyn's product is in the R&D stage.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/13991821 |
Identifiers & details
| Founded | 2015-9 |
|---|---|
| Employees (exact) | 4 |
| Status reason | Non Active, Dec 2022 ceased to operate |